|Age:||18 years or older|
|Keywords:||lymphoma, solid tumor malignancies, cancer|
|Type:||Drug study, Phase 1|
The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.
Exclusion Criteria: 1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody (mAb) should also be excluded. 2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. Prior surgery or radiotherapy within 14 days of study treatment 4. Receiving high-dose (e.g., > 10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of study treatment. NOTE: Inhaled, intranasal, intraocular, topical, and intraarticular steroids are allowed. Transient steroid administration as anti-emetic or chemotherapy pre-conditioning (e.g., for paclitaxel) is allowed per institutional guidelines. 4. Receiving therapeutic anticoagulation. NOTE: Low molecular weight heparin, Factor Xa inhibitors, and low-dose aspirin are allowed for deep vein thrombosis (DVT) prophylaxis. 5. History of autoimmune disease requiring systemic treatment or transplant that requires systemic steroids or immunosuppressive agents. NOTE: History of vitiligo, autoimmune thyroiditis, or mild psoriasis are allowed. 6. Known history of human immunodeficiency virus (HIV) or other chronic immunodeficiency 7. Uncontrolled intercurrent illness including, but not limited to: a. Uncontrolled diabetes with hemoglobin A1c (HgbA1c) ≥ 8.0% b. Ongoing or active bacterial, viral, or fungal infection requiring systemic treatment c. Clinically significant congestive heart failure defined by New York Heart Association (NYHA) Class 3 or Class 4 d. Unstable angina, arrhythmia, or myocardial infarction within 6 months prior to Screening 8. Known brain metastases or central nervous system (CNS) involvement. NOTE: Patients with asymptomatic and stable brain metastases following prior treatment may be eligible. 9. Other active malignancy requiring ongoing treatment 10. Women who are pregnant or breastfeeding